VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already ...
Antibody drug discovery is an extremely laborious and tedious process. Epitope Binning-seq, a novel method, introduces a groundbreaking approach by enabling simultaneous analysis of multiple ...
This article is based on a poster originally authored by Sophie Snow, Kira Freeman, Zaynab Isseljee, Alice Brankin and Christine Sanfelice, which was presented at ELRIG Drug Discovery 2024 in ...
The early identification of antibody candidates with desired affinities and dissociation kinetics, binding epitopes and critical quality attributes is vital for avoiding later-phase failures caused by ...
Epitope binning is an important step towards selecting the best monoclonal antibody for a specific therapeutic purpose as it allows researchers to narrow down the number of candidates by assessing ...
Monoclonal antibodies (mAbs) are one of the most successful therapeutic drug classes, generating lucrative sales for the pharmaceutical industry. In 2016, more than 20 therapeutic antibodies gained ...
Monoclonal antibodies are crucial therapeutics due to their high specificity and binding affinity for epitopes (the precise sites where an antibody attaches itself to an antigen, triggering an immune ...
The novel Epitope Binning-seq technology streamlines antibody epitope mapping and enables the simultaneous evaluation of large numbers of genetically encoded antibodies, grouping them into distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback